stockrow
Friday 6 November 2026
Export AKTX’s income statement to Excel — free account
Akari Therapeutics PLC
AKTX Healthcare Biotechnology
- EPS
- −11.4%
- Free cash flow
- +4.51%
- Total debt
- −1.00%
Quarter to June 2026, against a year earlier
7.95
0.20
+2.58%
Follow AKTX
Alert me
Akari Therapeutics PLC (AKTX) P/E ratio
Akari Therapeutics PLC has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 17.3× (October 2016) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|
Against its own ten years
Low 0.0×
High 17.3×
Ten-year median
0.0×
Current reading's percentile
98
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| LPCN Lipocine Inc. compare | n/m |
| ADAPY Adaptimmune Therapeutics PLC compare | n/m |
| BCDA BioCardia, Inc. compare | n/m |
| ATYR aTyr Pharma, Inc. compare | n/m |
| CASIF CASI Pharmaceuticals Inc. compare | n/m |
| DYAI Dyadic International Inc. compare | n/m |
| AKTX Akari Therapeutics PLC | n/m |
| KYNB Kyntra Bio Inc compare | 0.1× |
| RADX Radiopharm Theranostics Limited - Sponsored ADR compare | — |
| Biotechnology industry median | 10.6× |
| Healthcare sector median | 24.5× |
| Market median | 17.8× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)